| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 24 | 2022 | 362 | 4.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2022 | 1085 | 3.890 |
Why?
|
| Metabolic Syndrome | 13 | 2021 | 191 | 3.270 |
Why?
|
| Diabetes Mellitus | 12 | 2022 | 694 | 2.700 |
Why?
|
| Atherosclerosis | 13 | 2022 | 204 | 2.620 |
Why?
|
| Incretins | 12 | 2022 | 14 | 2.480 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 6 | 2022 | 14 | 2.430 |
Why?
|
| Cardiovascular Diseases | 14 | 2022 | 940 | 2.050 |
Why?
|
| Dyslipidemias | 7 | 2022 | 98 | 1.800 |
Why?
|
| Hypolipidemic Agents | 3 | 2019 | 82 | 1.170 |
Why?
|
| Inflammation | 7 | 2022 | 1030 | 1.160 |
Why?
|
| Diabetes Complications | 4 | 2021 | 249 | 1.130 |
Why?
|
| Hyperglycemia | 3 | 2022 | 158 | 1.080 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 6 | 2021 | 20 | 1.080 |
Why?
|
| Obesity | 6 | 2022 | 1076 | 1.060 |
Why?
|
| Thyroid Gland | 2 | 2017 | 67 | 1.030 |
Why?
|
| Humans | 87 | 2022 | 68618 | 1.020 |
Why?
|
| Thiazolidinediones | 4 | 2022 | 77 | 0.950 |
Why?
|
| Graves Disease | 2 | 2014 | 8 | 0.910 |
Why?
|
| Liraglutide | 6 | 2019 | 18 | 0.910 |
Why?
|
| Carotid Intima-Media Thickness | 4 | 2019 | 54 | 0.800 |
Why?
|
| Hypercalcemia | 3 | 2013 | 34 | 0.770 |
Why?
|
| Insulin Resistance | 8 | 2022 | 241 | 0.770 |
Why?
|
| Thyroiditis, Subacute | 2 | 2013 | 3 | 0.750 |
Why?
|
| Endothelium, Vascular | 3 | 2021 | 371 | 0.720 |
Why?
|
| Pituitary Neoplasms | 3 | 2011 | 52 | 0.720 |
Why?
|
| Torsades de Pointes | 2 | 2017 | 5 | 0.680 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 87 | 0.650 |
Why?
|
| Lipids | 5 | 2022 | 298 | 0.650 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2018 | 17 | 0.640 |
Why?
|
| Adenoma | 2 | 2012 | 132 | 0.610 |
Why?
|
| Vitamin D Deficiency | 2 | 2011 | 292 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2017 | 529 | 0.560 |
Why?
|
| Diabetes, Gestational | 2 | 2016 | 81 | 0.550 |
Why?
|
| Lipoproteins, LDL | 2 | 2021 | 343 | 0.550 |
Why?
|
| Neck Pain | 2 | 2013 | 15 | 0.550 |
Why?
|
| Lipoproteins | 2 | 2014 | 161 | 0.530 |
Why?
|
| Insulin | 7 | 2013 | 619 | 0.530 |
Why?
|
| Biomarkers | 7 | 2021 | 1593 | 0.520 |
Why?
|
| Vitamins | 2 | 2013 | 134 | 0.510 |
Why?
|
| Blood Glucose | 9 | 2021 | 631 | 0.510 |
Why?
|
| Adipokines | 2 | 2022 | 20 | 0.510 |
Why?
|
| Diagnosis, Differential | 8 | 2016 | 1140 | 0.510 |
Why?
|
| Dietary Supplements | 2 | 2019 | 332 | 0.500 |
Why?
|
| Glucosides | 1 | 2014 | 16 | 0.500 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 62 | 0.480 |
Why?
|
| Disease Management | 2 | 2007 | 248 | 0.480 |
Why?
|
| Intracranial Aneurysm | 1 | 2016 | 87 | 0.470 |
Why?
|
| Vitamin D | 3 | 2013 | 516 | 0.470 |
Why?
|
| Pandemics | 6 | 2022 | 352 | 0.460 |
Why?
|
| Calcium, Dietary | 1 | 2013 | 35 | 0.450 |
Why?
|
| Parathyroid Neoplasms | 1 | 2012 | 13 | 0.430 |
Why?
|
| Female | 32 | 2019 | 38074 | 0.420 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2012 | 1 | 0.420 |
Why?
|
| Nocardia asteroides | 1 | 2012 | 4 | 0.420 |
Why?
|
| Nocardia Infections | 1 | 2012 | 8 | 0.410 |
Why?
|
| Opportunistic Infections | 1 | 2012 | 33 | 0.410 |
Why?
|
| Risk Factors | 18 | 2021 | 5731 | 0.410 |
Why?
|
| Pituitary Apoplexy | 1 | 2011 | 4 | 0.400 |
Why?
|
| Pituitary Diseases | 1 | 2011 | 4 | 0.400 |
Why?
|
| Glucagon-Like Peptide 1 | 4 | 2016 | 17 | 0.360 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 30 | 0.360 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 186 | 0.350 |
Why?
|
| Acromegaly | 2 | 2012 | 5 | 0.340 |
Why?
|
| Hypoglycemia | 2 | 2010 | 72 | 0.340 |
Why?
|
| Middle Aged | 21 | 2019 | 21147 | 0.340 |
Why?
|
| Diabetic Nephropathies | 2 | 2012 | 161 | 0.330 |
Why?
|
| Orthopedic Procedures | 1 | 2010 | 102 | 0.320 |
Why?
|
| Glucose | 5 | 2021 | 307 | 0.320 |
Why?
|
| Drug-Eluting Stents | 3 | 2013 | 51 | 0.320 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 286 | 0.310 |
Why?
|
| Paclitaxel | 3 | 2013 | 140 | 0.310 |
Why?
|
| Gonadal Dysgenesis, 46,XX | 1 | 2008 | 1 | 0.310 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 2008 | 2 | 0.310 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 24 | 0.310 |
Why?
|
| Pyridines | 1 | 2010 | 261 | 0.310 |
Why?
|
| Sirolimus | 3 | 2013 | 118 | 0.310 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 244 | 0.310 |
Why?
|
| Treatment Outcome | 9 | 2021 | 7029 | 0.300 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 74 | 0.300 |
Why?
|
| Cholesterol, LDL | 3 | 2022 | 161 | 0.300 |
Why?
|
| Thyroid Hormones | 1 | 2007 | 31 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 331 | 0.290 |
Why?
|
| Cytokines | 2 | 2022 | 866 | 0.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.290 |
Why?
|
| Patient Care Team | 1 | 2009 | 311 | 0.290 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.290 |
Why?
|
| Sella Turcica | 1 | 2007 | 10 | 0.290 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2008 | 62 | 0.280 |
Why?
|
| Ofloxacin | 1 | 2006 | 15 | 0.280 |
Why?
|
| Aged | 15 | 2016 | 14862 | 0.270 |
Why?
|
| Meningeal Neoplasms | 1 | 2007 | 42 | 0.270 |
Why?
|
| Cardiovascular System | 2 | 2020 | 85 | 0.270 |
Why?
|
| Levofloxacin | 1 | 2006 | 23 | 0.270 |
Why?
|
| Meningioma | 1 | 2007 | 54 | 0.270 |
Why?
|
| Psychotic Disorders | 1 | 2007 | 157 | 0.270 |
Why?
|
| Insulin-Secreting Cells | 1 | 2006 | 41 | 0.270 |
Why?
|
| Nursing Assessment | 1 | 2006 | 70 | 0.260 |
Why?
|
| Diabetic Angiopathies | 2 | 2021 | 203 | 0.260 |
Why?
|
| Male | 21 | 2019 | 37321 | 0.260 |
Why?
|
| RNA, Viral | 2 | 2022 | 93 | 0.260 |
Why?
|
| Hypocalcemia | 1 | 2005 | 13 | 0.260 |
Why?
|
| Parathyroid Glands | 1 | 2005 | 22 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 100 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 212 | 0.240 |
Why?
|
| Animals | 13 | 2021 | 20881 | 0.240 |
Why?
|
| Ghrelin | 2 | 2014 | 8 | 0.230 |
Why?
|
| C-Reactive Protein | 4 | 2009 | 180 | 0.230 |
Why?
|
| Diabetic Ketoacidosis | 3 | 2014 | 20 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 1026 | 0.230 |
Why?
|
| Pregnancy | 3 | 2016 | 2334 | 0.230 |
Why?
|
| Health Promotion | 1 | 2007 | 407 | 0.220 |
Why?
|
| Body Weight | 3 | 2014 | 554 | 0.220 |
Why?
|
| Adult | 11 | 2016 | 21403 | 0.220 |
Why?
|
| Lymphoma | 1 | 2003 | 116 | 0.220 |
Why?
|
| Cost of Illness | 1 | 2004 | 206 | 0.210 |
Why?
|
| Oxidants | 1 | 2022 | 48 | 0.210 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2013 | 137 | 0.210 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 82 | 0.200 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2020 | 15 | 0.200 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 13 | 0.200 |
Why?
|
| Heart Failure | 1 | 2011 | 1180 | 0.200 |
Why?
|
| Pilot Projects | 4 | 2015 | 1342 | 0.200 |
Why?
|
| Macular Edema | 1 | 2022 | 21 | 0.200 |
Why?
|
| Proprotein Convertase 9 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Thiazoles | 1 | 2002 | 95 | 0.200 |
Why?
|
| Pituitary-Adrenal System | 1 | 2022 | 138 | 0.200 |
Why?
|
| South Carolina | 7 | 2014 | 2752 | 0.200 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 649 | 0.200 |
Why?
|
| Calcium | 3 | 2012 | 929 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 267 | 0.200 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2021 | 11 | 0.200 |
Why?
|
| Hypercholesterolemia | 1 | 2021 | 86 | 0.190 |
Why?
|
| Prevalence | 5 | 2016 | 1619 | 0.190 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 110 | 0.190 |
Why?
|
| Hypertension | 1 | 2010 | 1535 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 54 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 116 | 0.180 |
Why?
|
| Adipose Tissue | 2 | 2013 | 221 | 0.180 |
Why?
|
| Primary Health Care | 1 | 2006 | 703 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 170 | 0.180 |
Why?
|
| Metformin | 3 | 2016 | 63 | 0.180 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 434 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2019 | 3705 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2002 | 328 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 778 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2014 | 718 | 0.160 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 117 | 0.160 |
Why?
|
| Pancreatitis | 1 | 2020 | 279 | 0.150 |
Why?
|
| Perioperative Care | 2 | 2010 | 100 | 0.150 |
Why?
|
| Syncope | 1 | 2017 | 23 | 0.150 |
Why?
|
| Patient Care Planning | 2 | 2009 | 108 | 0.150 |
Why?
|
| Coronary Artery Disease | 2 | 2013 | 696 | 0.150 |
Why?
|
| United States | 4 | 2021 | 7367 | 0.150 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 125 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 98 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 332 | 0.140 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 425 | 0.140 |
Why?
|
| Interleukins | 2 | 2007 | 79 | 0.140 |
Why?
|
| Cooperative Behavior | 2 | 2008 | 235 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 83 | 0.130 |
Why?
|
| HIV Infections | 2 | 2014 | 791 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 514 | 0.130 |
Why?
|
| Heme Oxygenase-1 | 1 | 2014 | 40 | 0.120 |
Why?
|
| Alkalosis | 1 | 2014 | 5 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2014 | 21 | 0.120 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2014 | 21 | 0.120 |
Why?
|
| Azetidines | 1 | 2013 | 6 | 0.120 |
Why?
|
| Fibric Acids | 1 | 2013 | 12 | 0.120 |
Why?
|
| Ezetimibe | 1 | 2013 | 6 | 0.120 |
Why?
|
| Niacin | 1 | 2013 | 12 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 10 | 0.120 |
Why?
|
| Uric Acid | 1 | 2014 | 37 | 0.110 |
Why?
|
| Cerebrovascular Disorders | 1 | 2014 | 182 | 0.110 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 42 | 0.110 |
Why?
|
| Prehypertension | 1 | 2014 | 40 | 0.110 |
Why?
|
| Technetium | 1 | 2012 | 38 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 71 | 0.110 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 45 | 0.100 |
Why?
|
| Human Growth Hormone | 1 | 2012 | 20 | 0.100 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2012 | 14 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 100 | 0.100 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2012 | 30 | 0.100 |
Why?
|
| Pituitary Gland | 1 | 2011 | 29 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 160 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 711 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2014 | 792 | 0.100 |
Why?
|
| Pituitary Hormones | 1 | 2011 | 16 | 0.100 |
Why?
|
| Fever | 1 | 2012 | 96 | 0.100 |
Why?
|
| Drainage | 1 | 2012 | 133 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2007 | 1330 | 0.100 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 178 | 0.100 |
Why?
|
| Headache | 1 | 2011 | 68 | 0.100 |
Why?
|
| Time Factors | 5 | 2014 | 4655 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2014 | 1451 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2012 | 453 | 0.090 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2010 | 4 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 1046 | 0.090 |
Why?
|
| Adolescent | 5 | 2014 | 8912 | 0.090 |
Why?
|
| Genes, ras | 1 | 2010 | 46 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 31 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 37 | 0.090 |
Why?
|
| Niacinamide | 1 | 2010 | 31 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2011 | 112 | 0.090 |
Why?
|
| Comorbidity | 2 | 2014 | 1426 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 438 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.090 |
Why?
|
| Angiotensin II | 1 | 2010 | 220 | 0.080 |
Why?
|
| Everolimus | 3 | 2013 | 26 | 0.080 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 931 | 0.080 |
Why?
|
| Community Health Centers | 1 | 2008 | 26 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 1 | 2008 | 91 | 0.080 |
Why?
|
| Critical Care | 1 | 2010 | 263 | 0.080 |
Why?
|
| Infusion Pumps | 1 | 2007 | 39 | 0.070 |
Why?
|
| Young Adult | 3 | 2014 | 5717 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 780 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2013 | 2358 | 0.070 |
Why?
|
| Minority Groups | 1 | 2008 | 197 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 1 | 2007 | 30 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 4848 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 281 | 0.070 |
Why?
|
| Glucagon | 1 | 2006 | 22 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1851 | 0.070 |
Why?
|
| Myxedema | 1 | 2006 | 3 | 0.070 |
Why?
|
| Nursing Records | 1 | 2006 | 10 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 216 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2006 | 33 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2324 | 0.070 |
Why?
|
| Program Development | 1 | 2007 | 240 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2006 | 87 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 334 | 0.060 |
Why?
|
| Documentation | 1 | 2006 | 83 | 0.060 |
Why?
|
| Nurse's Role | 1 | 2006 | 66 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2006 | 107 | 0.060 |
Why?
|
| Pneumonia | 1 | 2006 | 110 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 218 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 2007 | 247 | 0.060 |
Why?
|
| Nurse Practitioners | 1 | 2006 | 90 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 626 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 502 | 0.060 |
Why?
|
| Phosphorus Metabolism Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Informed Consent | 1 | 2006 | 127 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 592 | 0.060 |
Why?
|
| Amenorrhea | 1 | 2004 | 16 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 772 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2004 | 28 | 0.060 |
Why?
|
| Patient Participation | 1 | 2006 | 146 | 0.060 |
Why?
|
| Hospitals | 1 | 2007 | 265 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2006 | 115 | 0.060 |
Why?
|
| Viral Load | 2 | 2014 | 127 | 0.060 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2022 | 7 | 0.050 |
Why?
|
| Child | 3 | 2014 | 6405 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 71 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 69 | 0.050 |
Why?
|
| Decision Making | 1 | 2006 | 410 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2013 | 249 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2022 | 3 | 0.050 |
Why?
|
| Public Health | 1 | 2004 | 201 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2022 | 16 | 0.050 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2022 | 48 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 133 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2022 | 150 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2022 | 144 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 64 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2013 | 301 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2022 | 241 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 536 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2014 | 7277 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2021 | 137 | 0.050 |
Why?
|
| Diet | 1 | 2004 | 514 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 330 | 0.050 |
Why?
|
| Epigenomics | 1 | 2021 | 29 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2022 | 291 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 219 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2022 | 222 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 376 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 371 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 193 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.040 |
Why?
|
| Logistic Models | 2 | 2014 | 1420 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 499 | 0.040 |
Why?
|
| Glucagon-Like Peptides | 1 | 2018 | 15 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 1266 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 2223 | 0.040 |
Why?
|
| Myocardial Infarction | 2 | 2013 | 807 | 0.040 |
Why?
|
| Overweight | 1 | 2019 | 186 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 7 | 0.040 |
Why?
|
| Italy | 1 | 2016 | 36 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2016 | 33 | 0.040 |
Why?
|
| Bronchi | 1 | 2017 | 59 | 0.040 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2016 | 6 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 36 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1118 | 0.030 |
Why?
|
| DNA | 1 | 2017 | 597 | 0.030 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2014 | 3 | 0.030 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2014 | 6 | 0.030 |
Why?
|
| Organic Anion Transporters | 1 | 2014 | 5 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 73 | 0.030 |
Why?
|
| Hyperuricemia | 1 | 2014 | 13 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 65 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 23 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2013 | 42 | 0.030 |
Why?
|
| Coronary Thrombosis | 1 | 2013 | 45 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 53 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2013 | 29 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 186 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 130 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 135 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 112 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 77 | 0.030 |
Why?
|
| Diabetic Neuropathies | 1 | 2012 | 33 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 90 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 184 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 618 | 0.030 |
Why?
|
| Medicaid | 1 | 2014 | 302 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 2689 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2013 | 114 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 83 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 226 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 186 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 110 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 159 | 0.020 |
Why?
|
| Thrombosis | 1 | 2012 | 218 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Transportation | 1 | 2008 | 21 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2008 | 99 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1864 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2008 | 201 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3259 | 0.020 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 14 | 0.020 |
Why?
|
| Self Care | 1 | 2008 | 253 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 2007 | 0.020 |
Why?
|
| Thyroxine | 1 | 2006 | 62 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 3187 | 0.020 |
Why?
|
| Health Personnel | 1 | 2008 | 286 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 848 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 955 | 0.020 |
Why?
|
| Rural Population | 1 | 2008 | 398 | 0.020 |
Why?
|
| Telemedicine | 1 | 2008 | 700 | 0.010 |
Why?
|